Axa’s Akebia Therapeutics AKBA Stock Holding History

Axa’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-627,892	Closed	-$1.21M	–	1120
2025 Q1	$1.21M	Buy	+627,892	New	+$1.28M	﹤0.01%	820
2020 Q3	–	Sell	-63,600	Closed	-$864K	–	1286
2020 Q2	$864K	Buy	63,600 +45,600	+253%	+$472K	﹤0.01%	979
2020 Q1	$136K	Buy	+18,000	New	+$140K	﹤0.01%	1129

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Axa's AKBA Position: Q2 2025 in Review

Axa sold out of Akebia Therapeutics (AKBA) in Q2 2025, closing a stake of 627,892 shares — an estimated $1.21M sold.

Axa first reported a position in AKBA in Q1 2020 and held it in 3 quarters. The position peaked at $1.21M in Q1 2025. 157 funds tracked by Wall St. Rank hold AKBA as of Q2 2025.

Axa reported no remaining Akebia Therapeutics position as of Q2 2025 after selling out during the quarter.
Axa sold 627,892 Akebia Therapeutics shares in Q2 2025, an estimated $1.21M.
Axa first reported a position in Akebia Therapeutics in Q1 2020 and held it in 3 quarters.
Axa's Akebia Therapeutics position peaked at $1.21M in Q1 2025.
157 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2025.

Based on Axa's 13F filing for Q2 2025, filed 14 Aug 2025.